MET inhibits the gluconeogenesis of hepatic glycogen, increases glucose uptake and utilization by peripheral tissues, improves hepatic insulin sensitivity and FG in patients with PCOS (22). The gene discussed is INS; the disease is polycystic ovary syndrome.